Management of Insomnia
First-Line Treatment: Cognitive Behavioral Therapy for Insomnia (CBT-I)
All adults with chronic insomnia must receive CBT-I as the initial treatment before or alongside any medication—this is a strong, non-negotiable recommendation that provides superior long-term efficacy with benefits sustained for up to 2 years after therapy ends, whereas medication effects cease when stopped. 1, 2, 3
Core Components of CBT-I (All Evidence-Based)
Stimulus control therapy – Use the bed only for sleep; if unable to fall asleep within approximately 20 minutes, leave the bedroom and engage in a quiet, non-stimulating activity until drowsy, then return to bed. 3, 4
Sleep restriction therapy – Limit time in bed to match actual total sleep time plus 30 minutes (minimum 5 hours), then adjust weekly based on sleep efficiency (total sleep time ÷ time in bed × 100%). This creates mild sleep deprivation that strengthens homeostatic sleep drive and consolidates sleep. 3, 5
Cognitive restructuring – Systematically challenge maladaptive beliefs about sleep (e.g., "I cannot function without 8 hours," "My life will be ruined if I can't sleep") using structured psychoeducation, Socratic questioning, and behavioral experiments. 3, 5
Relaxation techniques – Progressive muscle relaxation, guided imagery, or controlled breathing to lower physiological arousal; note that these may be counterproductive in some patients and are optional. 3, 4
Sleep hygiene education – Maintain a consistent sleep-wake schedule (including weekends), avoid caffeine ≥6 hours before bedtime, eliminate screen exposure ≥1 hour before sleep, keep the bedroom dark/cool/quiet, avoid evening alcohol, and avoid late exercise. 3, 5
Sleep hygiene education alone is insufficient as monotherapy and must be combined with stimulus control and sleep restriction to achieve sustained improvement. 1, 3
Delivery Formats (All Equally Effective)
- CBT-I can be delivered via individual therapy, group sessions, telephone-based programs, web-based modules, or self-help books—all formats demonstrate comparable efficacy, though therapist-led in-person programs show the highest remission rates. 2, 3
Pharmacologic Therapy: When and How to Add Medication
Pharmacotherapy is an adjunct to CBT-I, never a replacement, and should be prescribed at the lowest effective dose for the shortest duration (generally ≤4 weeks for acute insomnia per FDA labeling). 1, 2, 3
Treatment Algorithm by Insomnia Phenotype
For Sleep-Onset Insomnia
Ramelteon 8 mg – Melatonin-receptor agonist with no abuse potential, no DEA scheduling, and no withdrawal symptoms; preferred for patients with substance-use history. 2, 5
Zaleplon 10 mg (5 mg if age ≥65 years) – Ultrashort half-life (~1 hour) provides rapid sleep initiation with minimal next-day sedation; can be used for middle-of-night awakenings when ≥4 hours remain before planned awakening. 2, 5
Zolpidem 10 mg (5 mg if age ≥65 years) – Shortens sleep-onset latency by approximately 25 minutes and increases total sleep time by approximately 29 minutes; take within 30 minutes of bedtime with ≥7 hours remaining before awakening. 2, 5
For Sleep-Maintenance Insomnia
Low-dose doxepin 3–6 mg (≤6 mg if age ≥65 years) – This is the preferred first-line hypnotic for sleep-maintenance insomnia; reduces wake after sleep onset by 22–23 minutes, has minimal anticholinergic effects at hypnotic doses, and carries no abuse potential. 2, 3, 5
Suvorexant 10 mg – Orexin-receptor antagonist that reduces wake after sleep onset by 16–28 minutes with a lower risk of cognitive and psychomotor impairment than benzodiazepine-type agents. 2, 5
For Combined Sleep-Onset and Sleep-Maintenance Insomnia
Eszopiclone 2–3 mg (1 mg if age ≥65 years or hepatic impairment) – Increases total sleep time by 28–57 minutes and produces moderate-to-large improvements in subjective sleep quality; take within 30 minutes of bedtime with ≥7 hours remaining. 2, 5
Daridorexant – Orexin-receptor antagonist approved for use up to 3 months or longer in selected cases. 6, 7
Lemborexant – Another orexin-receptor antagonist with similar efficacy and duration recommendations. 6, 7
Monitoring and Reassessment
Reassess after 1–2 weeks to evaluate sleep-onset latency, total sleep time, nocturnal awakenings, daytime functioning, and adverse effects (somnolence, morning sedation, cognitive impairment, complex sleep behaviors). 2, 5
If the first-line agent fails after 1–2 weeks, switch to an alternative agent within the same class (e.g., zaleplon → zolpidem for onset; doxepin → suvorexant for maintenance). 2
If multiple first-line agents are ineffective, evaluate for underlying sleep disorders such as obstructive sleep apnea, restless-legs syndrome, periodic limb movement disorder, or circadian rhythm disorders. 2, 5
Medications Explicitly NOT Recommended
Trazodone
- The American Academy of Sleep Medicine issues a weak recommendation AGAINST trazodone because it yields only approximately 10 minutes reduction in sleep latency and approximately 8 minutes reduction in wake after sleep onset, provides no improvement in subjective sleep quality, and causes adverse events in approximately 75% of older adults (headache, somnolence). 1, 2, 3
Over-the-Counter Antihistamines
- Diphenhydramine and doxylamine are NOT recommended due to lack of efficacy data, strong anticholinergic effects (confusion, urinary retention, falls, daytime sedation, delirium—especially in older adults), and rapid tolerance development within 3–4 days. 1, 2, 3
Antipsychotics
- Quetiapine and olanzapine should NOT be used for insomnia; evidence for benefit is weak and they carry significant risks including weight gain, metabolic syndrome, extrapyramidal symptoms, and increased mortality in elderly patients with dementia. 1, 2, 3
Traditional Benzodiazepines
- Lorazepam, clonazepam, and diazepam are NOT recommended due to long half-lives leading to drug accumulation, prolonged daytime sedation, higher fall and cognitive-impairment risk, and associations with dementia and fractures. 2, 3, 8
Melatonin Supplements
- Melatonin supplements produce only approximately 9 minutes reduction in sleep latency and lack sufficient evidence for chronic insomnia treatment. 2, 3
Herbal Supplements
- Valerian, L-tryptophan, and other herbal preparations have insufficient evidence to support use for primary insomnia. 2, 3
Special Population Considerations
Older Adults (Age ≥65 Years)
Reduce all hypnotic doses: zolpidem ≤5 mg, eszopiclone ≤2 mg, zaleplon ≤5 mg, doxepin ≤6 mg. 2, 5, 8
Low-dose doxepin 3 mg and ramelteon 8 mg are the safest first-line options for older adults because they carry minimal fall risk and cognitive-impairment risk. 2, 8
Avoid all anticholinergic agents (OTC antihistamines, high-dose tricyclics) in older adults due to risk of confusion, urinary retention, falls, and delirium. 2, 8
Patients with Comorbid Depression or Anxiety
Sedating antidepressants (mirtazapine 7.5–30 mg, low-dose doxepin) may be considered as third-line options after benzodiazepine-receptor agonists have failed, especially when mood disorders are present. 2, 5
Sertraline is the preferred SSRI when treating comorbid depression due to lower QTc prolongation risk compared to citalopram/escitalopam. 2
Patients with Substance-Use History
Ramelteon 8 mg is the preferred agent because it has no abuse potential, is not DEA-scheduled, and causes no withdrawal symptoms. 2, 5
Avoid all benzodiazepines and benzodiazepine-receptor agonists in patients with substance-use history due to compounded abuse potential. 5
Critical Safety Warnings
Complex Sleep Behaviors
All benzodiazepine-receptor agonists (eszopiclone, zolpidem, zaleplon) carry FDA warnings for complex sleep behaviors (sleep-driving, sleep-walking, sleep-eating); discontinue the medication immediately if these occur. 2, 5
Alcohol must be avoided while using these agents because it markedly increases the risk of complex sleep behaviors and respiratory depression. 2
Falls, Fractures, and Cognitive Decline
All hypnotics increase the risk of falls, fractures, and cognitive impairment, especially in adults ≥65 years. 2, 8
Observational data suggest a possible association between hypnotic use and higher dementia risk, though causality remains unproven. 2
Polypharmacy Risks
- Combining multiple sedating agents (e.g., adding a benzodiazepine to doxepin) markedly increases the risk of respiratory depression, cognitive impairment, falls, and complex sleep behaviors—such combinations should be avoided. 2, 5
Duration of Use
FDA labeling limits hypnotic use to ≤4 weeks for acute insomnia; evidence for longer durations is insufficient. 2, 3, 7
Orexin-receptor antagonists (suvorexant, daridorexant, lemborexant) may be continued for up to 3 months or longer in selected cases. 6, 7
Prolonged-release melatonin 2 mg can be used for up to 3 months in patients ≥55 years. 7
Common Clinical Pitfalls to Avoid
Starting pharmacotherapy without first implementing CBT-I violates strong guideline recommendations and yields less durable benefit. 2, 3
Using adult dosing in older adults increases fall risk; age-adjusted dosing is mandatory. 2, 8
Prescribing trazodone, OTC antihistamines, or antipsychotics for primary insomnia despite lack of efficacy and significant safety concerns. 1, 2, 3
Continuing hypnotics beyond 4 weeks without periodic reassessment contradicts FDA labeling and guideline advice. 2, 3
Failing to match medication to insomnia phenotype—use zaleplon/ramelteon/zolpidem for sleep-onset difficulty, low-dose doxepin/suvorexant for sleep-maintenance difficulty, and eszopiclone/daridorexant for combined symptoms. 2, 5
Combining multiple sedative agents creates dangerous polypharmacy with additive CNS depression, respiratory risk, falls, and cognitive impairment. 2, 5
Failing to evaluate for underlying sleep disorders (sleep apnea, restless-legs syndrome, circadian rhythm disorders) when insomnia persists beyond 7–10 days despite appropriate treatment. 2, 5